UCB's bimekizumab meets in Phase IIb for psoriasis

UCB S.A. (Euronext:UCB) reported top-line data from the Phase IIb BE ABLE trial in 250 patients with moderate to severe chronic plaque psoriasis showing that subcutaneous bimekizumab (UCB4940) every 4 weeks met the primary endpoint of a greater proportion of patients who achieved a Psoriasis Area and Severity Index (PASI) 90 response at week 12 vs. placebo. UCB said up to 79% of patients who received bimekizumab achieved a PASI 90 response at week 12. On a secondary endpoint, up to 60% of patients who received bimekizumab achieved a PASI 100 response at week 12.

Other secondary endpoints in the double-blind, international trial include the proportion of patients with an Investigator’s Global Assessment (IGA) response defined as clear or almost clear skin with a ≥2-category improvement from baseline at weeks 8 and 12, PASI 90 response at week 8 and PASI 75 response at week 12. Patients received placebo or 1 of 5 dose levels of bimekizumab. Final data from BE ABLE are expected early next year...